Alliances
To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.
Phase 1/2 trials expected to initiate 1Q2019
Hutchison China MediTech Limited today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect.
Medopad, a U.K.-based medical firm, and China-based Tencent Holdings, have teamed up on a project that will attempt to harness artificial intelligence in the diagnosis of Parkinson’s disease.
Seattle Genetics and its development partner Takeda recently announced stellar Phase III data from its ECHELON-2 clinical trial of Adcetris for peripheral T-cell lymphoma. Clay Siegall, president and CEO of Seattle Genetics, took time to speak with BioSpace about the approval and plans for the drug.
Yesterday, Evotec AG (EVT) announced that Sanofi will be participating in an organized Public Private Partnership (PPP) that involves the initiation of brand newly formed BRIDGE, or LAB031, which was created to further the discovery of therapeutic drugs in multiple areas.
Evotec AG announced today that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas.
Ingenza has announced that its collaboration with Syngenta for work on efficient technologies to support the development of crop protection products has been extended.
Dr. Amin Al Amiri: the Programs are part of ministry’s initiatives during ‘Year of Zayed’ to provide quality of care to patients
Arrowhead announced a deal with Johnson & Johnson that could conceivably be worth over $3.7 billion, with J&J agreeing to pick up a minor stake in the company, including the task of cultivating and promoting its ARO-HBV Hepatitis B drug.
PRESS RELEASES